Vaccinia

01/01/2019 - "The most promising vaccine candidates that have advanced into pre-clinical models and the clinic to eliminate or provide protection against these chronic viruses are viral vectors [e.g., recombinant cytomegalovirus, Adenovirus, and modified vaccinia Ankara (MVA)]. "
10/01/2018 - "Vaccinia-based platforms show considerable promise for the development of multi-valent and multi-pathogen vaccines, especially with recent developments in vector technologies and manufacturing processes. "
09/01/2022 - "According to the available documents, we found two replication-competent and one replication-deficient vaccinia vaccines were effective against Orthopoxvirus. "
01/01/2004 - "Analysis of the movement linked to cytoskeleton may lead to: (I) improved understanding of the mechanisms of disease transmission, including carriers and carrier states, pathogen movements, environmental factors and pharmacokinetics of the uptake and residues of vaccines and other biologics, and drugs in cultivated organisms; (II) new therapeutic developments, since it identifies the molecular targets involved in the pathogenicity of Listeria and Shigella and vaccinia intracellular enveloped virus. "
04/03/2013 - "The protective efficacy of the vaccine was not affected by pre-existing immunity to vaccinia. "

11/01/1997 - "When the protective efficacy of VP2 and VP5 was tested in sheep, vaccinia-expressed VP2, VP5 and VP2 + VP5 were protective, with the most consistent protection being in groups immunized with both proteins."
02/09/2007 - "Two or more doses of MVA prior to Dryvax reduced severity of lesion formation, decreased magnitude and duration of viral shedding, and augmented post-Dryvax vaccinia-specific CD8(+) T cell responses and extracellular enveloped virus protein-specific antibody responses. "
01/01/2018 - "Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization."
01/08/2010 - "Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge."
03/01/2009 - "Recombinant MVA technology can be improved greatly by combining transient host-range selection (based on the restoration in MVA of the deleted vaccinia gene K1L) with the differential expression of fluorescent proteins. "

06/01/2004 - "Efficacy of cidofovir in a murine model of disseminated progressive vaccinia."
11/01/2016 - "Especially, 24b11 displayed the most potent inhibitory activity against vaccinia with an EC50 value of 1.7μM, which was 15 fold than that of the reference drug Cidofovir (EC50=25μM). "
01/01/2006 - "Cidofovir was found to have an EC50 of 20 microM and 32 microM against vaccinia and cowpox virus, respectively. "
01/01/2005 - "The wild-type (WT) vaccinia (WR strain) virus is highly virulent to mice by intranasal inoculation, yet death can be prevented by cidofovir treatment. "
09/15/2004 - "Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice."

12/01/1994 - "We have previously expressed this glycoprotein as a vaccinia recombinant virus and have shown that the HA glycoprotein synthesized is indistinguishable from that coded by MV. In the present study, we report that in RK13 cells a soluble form (sHA) of the HA is secreted into the medium. "
10/01/1990 - "Vaccinia recombinant virus expressing the rabies virus glycoprotein: safety and efficacy trials in Canadian wildlife."
01/01/2022 - "To address this goal, we generated a Modified Vaccinia Ankara (MVA) recombinant virus expressing a truncated form of glycoprotein B (gBΔfur731) from EEHV1A, the strain associated with the majority of lethal EEHV cases. "
01/01/2022 - "Modified vaccinia Ankara expressing EEHV1A glycoprotein B elicits humoral and cell-mediated immune responses in mice."
04/28/2016 - "We then assessed the effect of adding a booster dose of a modified vaccinia Ankara (MVA) strain, encoding the same Ebola virus glycoprotein, in 30 of the 60 participants and evaluated a reduced prime-boost interval in another 16 participants. "

01/01/2023 - "No study reports individual patient data for vaccinia immune globulin. "
09/01/2005 - "The study suggests that the candidate BRP batch 1 is suitable as a reference preparation for the potency assay of vaccinia immunoglobulin by the plaque reduction neutralisation method, using cell-adapted vaccinia virus. "
03/15/2003 - "Almost all cases were treated with vaccinia immune globulin, but its efficacy has never been tested in a placebo-controlled trial. "
09/22/2023 - "Vaccinia immune globulin was approved by the U.S. "
01/01/2022 - "Three guidelines advised on vaccinia immune globulin as PEP for severe cases in people with immunosuppression. "

11/01/2008 - "In this study, we show the utility of stepwise rapid plate assays that (i) screen for compounds that block vaccinia DNA synthesis, (ii) eliminate trivial inhibitors, e.g. "
12/01/2007 - "In the present study we evaluated the effect of three different immunogens--recombinant vaccinia, recombinant adenovirus, and plasmid DNA--on the generation of memory cellular immune responses. "
01/01/2006 - "In the study reported here, animals were primed with DNA followed by one booster immunization with Semliki Forest Virus (SFV) and two immunizations with modified Vaccinia Ankara (MVA). "
04/03/2000 - "Our results encourage the use of the DNA prime/vaccinia booster regimen in future clinical trials."
04/01/1988 - "To study the genetic basis for this difference in host range, recombinants between vaccinia and cowpox viruses were isolated and their DNA restriction patterns were examined. "

05/01/2014 - "In this study, we assessed fusion of the HCV NS antigen to murine and human Ii expressed by the chimpanzee adenovirus vector ChAd3 or recombinant modified vaccinia Ankara in mice and nonhuman primates (NHPs). "
10/24/2007 - "Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials."
05/01/2003 - "The recombinant vaccinia-based assay is a rapid, sensitive and quantitative test and is thus suitable for the detection of functional antigen-specific CD8(+) CTL in large-scale clinical studies."
11/30/1936 - "STUDIES ON THE SOLUBLE PRECIPITABLE SUBSTANCES OF VACCINIA : III. THE PRECIPITIN RESPONSES OF RABBITS TO THE LS ANTIGEN OF VACCINIA."
01/30/2023 - "Herein, we report a heterologous vaccination strategy against IBV, where QAC-encapsulated plasmid immunization is followed by Modified Vaccinia Ankara (MVA) immunization, both expressing the same IBV-N antigen. "

09/01/2005 - "In accordance with this genomic background, m8 induced 100% protection against a highly pathogenic vaccinia WR virus in mice by a single vaccination, despite the lack of anti-B5R and anti-EEV antibodies. "
08/01/1989 - "Previous studies demonstrated that passively acquired RSV antibodies can suppress the immune response and the protective efficacy of vaccinia-RSV recombinants administered by the intradermal route. "
01/01/2005 - "We have chosen to develop and validate the "gold standard method" (plaque reduction neutralization assay) to titrate neutralizing anti-vaccinia antibodies in two different French laboratories belonging to the Department of Defense (CRSSA) and to the French Health Products Safety Agency (Afssaps). "
12/01/2005 - "A Proficiency Testing Study (PTS) was organized in France by the French Health Products Safety Agency (Afssaps) aiming at assessing the performance of laboratories in performing a neutralizing anti-vaccinia antibodies titration method by plaque reduction neutralization test (PRNT). "
01/21/1999 - "The titers of vaccinia antibodies induced in vaccinees without detectable antibodies at the start of the study, were significantly lower and the titers observed after re-vaccination were: 62, 56, 66, 38 and 34, at 14, 21, 30, 45 and 60 d, respectively. "

01/01/2016 - "Intriguingly, the induction of this cross-reactive immunity leads to significant reduction of viral loads in a recombinant vaccinia-HCV virus infected mouse model, supporting their role in antiviral immunity against HCV. "
01/01/1976 - "BHK-21 cells persistently infected with either vaccinia or foot and mouth disease virus were used to study the efficacy of antiviral compounds. "
07/01/2011 - "Core viral functions are conserved among orthopoxviruses, and consequently Vaccinia is routinely used to study poxvirus biology and screen for novel antiviral compounds. "
03/01/1969 - "Study of antiviral activity of tender leaves of Margosa tree (Melia azadericta) on vaccinia and variola virus: a preliminary report."
03/23/2023 - "Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts."

01/02/2007 - "Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine."
01/01/2016 - "A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects."
01/01/2016 - "Erratum: Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial."
11/09/2015 - "To conduct a post-marketing surveillance study of the vaccination of freeze-dried live attenuated smallpox vaccine prepared in cell culture LC16-KAKETSUKEN using attenuated vaccinia strain LC16m8. "
04/01/2015 - "The focus of this study was to compare the safety and immunogenicity of a replication-deficient, highly attenuated smallpox vaccine modified vaccinia Ankara (MVA) in HIV-infected and healthy subjects. "

01/01/2023 - "The intrapleural administration of oncolytic vaccinia viral therapy is safe and feasible and generates regional immune response without overt systemic symptoms. "
04/12/2016 - "We therefore sought to influence the type and level of immune response raised after oncolytic vaccinia therapy through manipulation of TLR signaling. "
09/01/2014 - "It was observed that prevention of angiogenesis mediated by oncolytic vaccinia can be utilized to enhance the TKI therapy. "
01/01/2012 - "Fully human mAbs (hmAbs) against vaccinia H3 (H3L) and B5 (B5R), targeting both the mature virion (MV) and extracellular enveloped virion (EV) forms, have been developed as potential therapeutics for use in humans. "
05/01/2011 - "The main achievements of each field are summarized with a special emphasis on vaccinia as an oncolytic vector and its combination therapies. "

01/01/1977 - "A new approach in immunotherapy with Vaccinia oncolysates."
10/15/2002 - "Patients with high-risk melanoma treated by immunotherapy with vaccinia viral lysates were found in phase II studies to have improved survival compared with historical controls. "
01/01/2012 - "Our findings clearly demonstrate the role of T cells in regulating pulmonary fibrosis as well as suggest that vaccinia-induced immunotherapy in the lung may prove to be a novel treatment approach to this otherwise fatal disease."
10/15/2002 - "Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial."
10/01/2001 - "The role of wild type vaccinia as immunotherapy for bladder cancer warrants further study. "

11/01/2005 - "We conclude that this recombinant vaccinia vSP shows promise for oncolytic virus therapy. "
01/01/2023 - "Global trends of Vaccinia oncolytic virus therapy over the past two decades: Bibliometric and visual analysis."
01/01/2019 - "However, the efficacy as oncolytic virotherapy of Chinese vaccinia strain Tian Tan (VTT) has not been reported. "
01/01/2021 - " shows broad efficacy against orthopoxviruses in vitro and in vivo and could be developed for use against emerging orthopoxvirus diseases such as monkeypox, vaccination-associated adverse events, and side effects of vaccinia oncolytic virus therapy."
06/15/2012 - "Recombinant vaccinia oncolytic virotherapy could provide a new platform for the treatment of patients with bone and soft tissue sarcomas. "

01/01/1977 - "These results are discussed in relation to in vivo experiments: retardation of tumour growth was noted in mice which had received several injections of vaccinia or Moloney virus, showing that the new CML targets were probably acting as transplantation targets."
05/01/1977 - "Four daily injections of the complex exerted virtually no effect on the course of vaccinia infection. "
11/08/1994 - "This work suggests that enteric-coated recombinant vaccinia could be an orally administered, inexpensive, multivalent, temperature-stable, safe, and effective vaccine for children that could be particularly useful in developing nations, where multiple injections are not easily administered. "
01/01/1992 - "Research results also indicate that a recombinant vaccine in a live vector such as vaccinia would require less frequent injections, and elicit a high antibody response capable of preventing pregnancy. "
09/01/1999 - "Seven immunocompetent, revaccinated patients with surgically incurable cutaneous melanoma underwent treatment of dermal and/or subcutaneous metastases with twice-weekly intratumoral injections of escalating doses (10(4)-2 x 10(7) plaque-forming units (PFU)/lesion; 10(4)-8 x 10(7) PFU/session) of a vaccinia/GM-CSF recombinant virus for 6 weeks. "

01/01/1988 - "Despite this protection, at least 99% of the test inoculum of two susceptible viruses (vaccinia and herpes simplex) was found to be inactivated after treatment and the subsequent dissociation of virus/antibody complexes. "
04/01/2005 - "We also demonstrated that mice with 1 cm subcutaneous tumors treated with a systemically delivered, conditionally replicating vaccinia under conditions of hyperthermia had complete tumor regression in 50% and significantly improved antitumor response, compared with normothermic viral-treated controls (mean tumor volume of 110 mm(3) vs 3169 mm(3), 13 days after treatment) and compared with hyperthermic, nonvirally treated control animals (p < 0.0001). "
01/01/2020 - "We administered Ad26, modified vaccinia Ankara vectors containing mosaic HIV-1 antigens or placebo in 26 individuals who initiated antiretroviral therapy during acute human immunodeficiency virus infection as an exploratory study to determine the safety and duration of viremic control after treatment interruption. "
10/31/1940 - "Simple washing after treatment seemed to remove the coating of serum proteins, at least in part, from both collodion particles and elementary bodies of vaccinia."
03/14/2023 - "Successful Outcome after Treatment with Cidofovir, Vaccinia, and Extended Course of Tecovirimat in a Newly-Diagnosed HIV Patient with Severe Mpox: A Case Report."